Short Report

You have full text access to this OnlineOpen article

Nadir B cell counts are significantly correlated with the risk of Kaposi's sarcoma

  1. Justin Stebbing†,*,
  2. Brian Gazzard,
  3. Tom Newsom-Davis,
  4. Mark Nelson,
  5. Steve Patterson,
  6. Frances Gotch,
  7. Sundhiya Mandalia,
  8. Mark Bower

Article first published online: 28 OCT 2003

DOI: 10.1002/ijc.11601

Issue

International Journal of Cancer

International Journal of Cancer

Volume 108, Issue 3, pages 473–474, 20 January 2004

Additional Information

How to Cite

Stebbing, J., Gazzard, B., Newsom-Davis, T., Nelson, M., Patterson, S., Gotch, F., Mandalia, S. and Bower, M. (2004), Nadir B cell counts are significantly correlated with the risk of Kaposi's sarcoma. Int. J. Cancer, 108: 473–474. doi: 10.1002/ijc.11601

Author Information

  1. Department of Immunology, Division of Investigative Science, Faculty of Medicine, Imperial College of Science, Technology and Medicine, The Chelsea and Westminster Hospital, London, United Kingdom

  1. †

    Fax:+011-44-208-746-5997

*Department of Immunology, The Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, United Kingdom

Publication History

  1. Issue published online: 21 NOV 2003
  2. Article first published online: 28 OCT 2003
  3. Manuscript Accepted: 12 SEP 2003
  4. Manuscript Received: 14 AUG 2003

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (57K)

REFERENCES

  • 1
    Lane HC, Masur H, Edgar LC, Whalen G, Rook AH, Fauci AS. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med 1983;309: 453–8.
  • 2
    Shirai A, Cosentino M, Leitman-Klinman SF, Klinman DM. Human immunodeficiency virus infection induces both polyclonal and virus-specific B cell activation. J Clin Invest 1992;89: 561–6.
  • 3
    Amadori A, De Silvestro G, Zamarchi R, Veronese ML, Mazza MR, Schiavo G, Panozzo M, DeRossi A, Ometto L, Mous J. CD4 epitope masking by gp120/anti-gp120 antibody complexes. A potential mechanism for CD4+ cell function down-regulation in AIDS patients. J Immunol 1992;148: 2709–16.
  • 4
    Martinez-Maza O, Crabb E, Mitsuyasu RT, Fahey JL, Giorgi JV. 1987. Infection with the human immunodeficiency virus (HIV) is associated with an in vivo increase in B lymphocyte activation and immaturity. J Immunol 1987;138: 3720–4.
  • 5
    Forster R, Schweigard G, Johann S, Emrich T, Kremmer E, Nerl C, Lipp M. Abnormal expression of the B-cell homing chemokine receptor BLR1 during the progression of acquired immunodeficiency syndrome. Blood 1997;90: 520–5.
  • 6
    Muro-Cacho CA, Pantaleo G, Fauci AS. 1995. Analysis of apoptosis in lymph nodes of HIV-infected persons. Intensity of apoptosis correlates with the general state of activation of the lymphoid tissue and not with stage of disease or viral burden. J Immunol 1995;154: 5555–66.
  • 7
    Samuelsson A, Brostrom C, van Dijk N, Sonnerborg A, Chiodi F. Apoptosis of CD4+ and CD19+ cells during human immunodeficiency virus type 1 infection—correlation with clinical progression, viral load, and loss of humoral immunity. Virology 1997;238: 180–8.
  • 8
    Conge AM, Tarte K, Reynes J, Segondy M, Gerfaux J, Zembala M, Vendrell AP. 1998. Impairment of B-lymphocyte differentiation induced by dual triggering of the B-cell antigen receptor and CD40 in advanced HIV-1-disease. AIDS 1998;12: 1437–49.
  • 9
    Ballet JJ, Sulcebe G, Couderc LJ, Danon F, Rabian C, Lathrop M, Seligmann M. Impaired anti-pneumococcal antibody response in patients with AIDS-related persistent generalized lymphadenopathy. Clin Exp Immunol 1987;68: 479–87.
  • 10
    Miotti PG, Nelson KE, Dallabetta GA, Farzadegan H, Margolick J, Clements ML. 1989. The influence of HIV infection on antibody responses to a two-dose regimen of influenza vaccine. JAMA 1989;262: 779–83.
  • 11
    Opravil M, Fierz W, Matter L, Blaser J, Luthy R. 1991. Poor antibody response after tetanus and pneumococcal vaccination in immunocompromised, HIV-infected patients. Clin Exp Immunol 1991;84: 185–9.
    Direct Link:
  • 12
    Malaspina A, Moir S, Kottilil S, Hallahan CW, Ehler LA, Liu S. 2003. Deleterious effect of HIV-1 plasma viremia on B cell costimulatory function. J Immunol 2003;170: 5965–72.
  • 13
    Moir S, Ogwaro KM, Malaspina A, Vasquez J, Donoghue ET, Hallahan CW. 2003. Perturbations in B cell responsiveness to CD4+ T cell help in HIV-infected individuals. Proc Natl Acad Sci USA 2003;100: 6057–62.
  • 14
    Portsmouth S, Stebbing J, Gill J, Mandalia S, Bower M, Nelson M, Gazzard B. A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma. AIDS 2003;17: F17–22.
  • 15
    Wilkinson J, Cope A, Gill J, Bourboulia D, Hayes P, Imami N. 2002. Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy. J Virol 2002;76: 2634–40.
  • 16
    Stebbing J, Bourboulia D, Johnson M, Henderson S, Williams I, Wilder N, Tyrer M, Youle M, Imami N, Kobu T, Kuon W, Sieper J, Gotch F, et al. Kaposi's sarcoma-associated herpesvirus cytotoxic T lymphocytes recognize and target Darwinian positively selected autologous K1 epitopes. J Virol 2003;77: 4306–14.
  • 17
    Sirianni MC, Vincenzi L, Topino S, Giovannetti A, Mazzetta F, Libi F, Ensoli B. NK cell activity controls human herpesvirus 8 latent infection and is restored upon highly active antiretroviral therapy in AIDS patients with regressing Kaposi's sarcoma. Eur J Immunol 2002;32: 2711–20.
    Direct Link:
  • 18
    Stebbing J, Gazzard B, Flore O, Thomas C, Benlarech A, Mandalia S, Bower M, Gotch F, Patterson S. Natural killer cells are not infected by Kaposi's sarcoma-associated herpesvirus in vivo, and natural killer cell counts do not correlate with the risk of developing Kaposi's sarcoma. AIDS 2003;17: 1998–2000.
View Full Article (HTML) Get PDF (57K)